- Full Year 2022 Total Revenue of $619.0 million; Q4 Total
Revenue of $67.7 million
- Full Year 2022 Core Revenue grows 95% year-over-year to $181.5
million; Q4 Core Revenue grows 97% year-over-year to $55.0
million
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”, or the
“Company”), a technology-based company with a well-established
clinical diagnostic business and a therapeutic development
business, today announced financial results for its fourth quarter
and full year ended December 31, 2022.
Fourth Quarter 2022 Results:
- Total Revenue of $67.7 million
- Core Revenue1 grew 97% year-over-year to $55.0 million
- GAAP loss of $23.8 million, or $0.80 per share
- Non-GAAP loss of $14.2 million, or $0.48 per share
- Adjusted EBITDA loss of $15.1 million
- Cash from operations of $33.2 million
- Cash, cash equivalents, and investments in marketable
securities, including investments pending settlement, of $872.0
million as of December 31, 2022
- Repurchased approximately 815,000 shares of common stock at an
aggregate cost of $29.1 million under the stock repurchase program
announced in March 2022
Full Year 2022 Results:
- Total Revenue of $619.0 million
- Core Revenue1 grew 95% year-over-year to $181.5 million
- GAAP income of $143.4 million, or $4.63 per share
- Non-GAAP income of $179.4 million, or $5.79 per share
- Adjusted EBITDA of $257.1 million
- Cash from operations of $253.5 million
- Repurchased over 1.8 million shares of common stock at an
aggregate cost of $74.3 million under the stock repurchase program
announced in March 2022
Note:
1) Core Revenue excludes revenue from
COVID-19 testing products and services including COVID-19 NGS
testing revenue.
Non-GAAP income (loss), non-GAAP income (loss) per share, and
adjusted EBITDA income (loss) are described below under “Note
Regarding Non-GAAP Financial Measures” and are reconciled to the
most directly comparable GAAP financial measure, GAAP income
(loss), in the accompanying tables.
Ming Hsieh, Chairman of the Board and Chief Executive Officer,
said, “2022 was a transitional and transformative year for Fulgent,
as we integrated the acquisitions of Inform Diagnostics and CSI
Laboratories and acquired the Pharma business. As the COVID-19
pandemic continues to have a lesser impact, we are excited about
the growth and momentum in our core business, with strength across
our 3 business areas - precision diagnostics, anatomic pathology,
and pharma services - and momentum in oncology and reproductive
health, particularly with the expansion of oncologic carrier
screening through Beacon787, also announced today. We have
reorganized our Board of Directors and are on the path to
transforming Fulgent from a genomic diagnostic service business
into a fully integrated precision medicine company, focusing on
oncology. In the meantime, we have a long runway of opportunity in
the core business and see diagnostics as a dependable source of
revenue and growth for Fulgent in the years ahead.”
Paul Kim, Chief Financial Officer, said, “We are pleased with
our results in 2022 and the trajectory of our core business. While
the revenue profile of the Company without COVID testing revenue
has implications for our bottom line, I believe we are poised for
sustainable growth in the core business and to continue to generate
cash. We are well positioned to execute our strategy while
maintaining flexibility to capitalize on additional acquisition and
strategic investment opportunities in the future.”
Outlook:
For the first quarter of 2023, Fulgent expects:
- Total Revenue of approximately $56.0 million
For the full year 2023, Fulgent expects:
- Total Revenue of approximately $240.0 million
- GAAP loss of approximately $2.50 per share
- Non-GAAP loss of approximately $1.25 per share
Conference Call Information
Fulgent will host a conference call for the investment community
today at 4:30 PM ET (1:30 PM PT) to discuss its fourth quarter and
full year 2022 results. The call may be accessed through a live
audio webcast in the Investor Relations section of the Company’s
website, http://ir.fulgentgenetics.com. An audio replay will be
available at the same location.
Note Regarding Non-GAAP Financial Measures
Certain information set forth in this press release, including
non-GAAP income (loss), non-GAAP income (loss) per share, and
adjusted EBITDA income (loss) are non-GAAP financial measures.
Fulgent believes this information is useful to investors because it
provides a basis for measuring the performance of the Company’s
business, excluding certain income or expense items that management
believes are not directly attributable to the Company’s operating
results. Fulgent defines non-GAAP income (loss) as net income
(loss) calculated in accordance with accounting principles
generally accepted in the United States of America, or GAAP, plus
amortization of intangible assets, plus restructuring costs, plus
acquisition-related costs, including banking fees and legal fees
associated with the recent acquisitions, plus equity-based
compensation expense, plus or minus the non-GAAP tax effect, and
plus or minus other charges or gains, as identified, that
management believes are not representative of the Company’s
operations. The non-GAAP tax effect is calculated by applying the
statutory corporate tax rate on the amortization of intangible
assets, restructuring costs, acquisition-related costs, and
equity-based compensation expense. Fulgent defines adjusted EBITDA
income (loss) as GAAP income (loss) plus or minus interest
(expense) income, plus or minus provisions (benefits) for income
taxes, plus restructuring costs, plus acquisition-related costs,
plus equity-based compensation expense, plus depreciation and
amortization, and plus or minus other charges or gains, as
identified, that management believes are not representative of the
Company’s operations. Fulgent may continue to incur expenses
similar to the items added to or subtracted from GAAP income (loss)
to calculate non-GAAP income (loss) and adjusted EBITDA income
(loss); accordingly, the exclusion of these items in the
presentation of these non-GAAP financial measures should not be
construed as an implication that these items are unusual,
infrequent or non-recurring. Management uses these non-GAAP
financial measures along with the most directly comparable GAAP
financial measure of net income (loss) in evaluating the Company's
operating performance. Non-GAAP financial measures should not be
considered in isolation from, or as a substitute for, financial
information presented in conformity with GAAP, and non-GAAP
financial measures as reported by Fulgent may not be comparable to
similarly titled metrics reported by other companies.
About Fulgent
Fulgent is a technology-based company with a well-established
clinical diagnostic business and a therapeutic development
business. Fulgent’s clinical diagnostic business offers molecular
diagnostic testing services, comprehensive genetic testing, and
high-quality anatomic pathology laboratory services designed to
provide physicians and patients with clinically actionable
diagnostic information to improve the quality of patient care.
Fulgent’s therapeutic development business is focused on developing
drug candidates for treating a broad range of cancers using a novel
nanoencapsulation and targeted therapy platform designed to improve
the therapeutic window and pharmacokinetic profile of new and
existing cancer drugs. The Company aims to transform from a genomic
diagnostic business into a fully integrated precision medicine
company.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Examples of forward-looking statements in this press release
include statements about, among other things: future performance,
guidance regarding, expected quarterly and annual financial
results, including total revenues, GAAP loss, and non-GAAP loss;
evaluations and judgments regarding the stability of certain
revenue sources, momentum, vision, future opportunities, trajectory
acquisition strategies, strategic investment strategies, synergies
related to and the performance of acquired businesses (including
Inform Diagnostics, CSI Laboratories, and Pharma), investments and
partnerships, relationships and the Company’s testing services and
technology; future growth and the Company’s testing services and
technologies and expansion; the Company’s identification and
evaluation of opportunities and its ability to capitalize on
opportunities, capture market share, or to expand its presence in
certain markets; and the Company’s ability to continue to grow its
business.
Forward-looking statements are statements other than historical
facts and relate to future events or circumstances or the Company’s
future performance, and they are based on management’s current
assumptions, expectations, and beliefs concerning future
developments and their potential effect on the Company’s business.
These forward-looking statements are subject to a number of risks
and uncertainties, which may cause the forward-looking events and
circumstances described in this press release to not occur, and
actual results to differ materially and adversely from those
described in or implied by the forward-looking statements. These
risks and uncertainties include, among others: the market potential
for, and the rate and degree of market adoption of, the Company’s
tests, including its Beacon787 panel; its ability to maintain
turnaround times and otherwise keep pace with rapidly changing
technology; the Company’s ability to maintain the low internal
costs of its business model; the Company’s ability to maintain an
acceptable margin; risks related to volatility in the Company’s
results, which can fluctuate significantly from period to period;
risks associated with the composition of the Company’s customer
base, which can fluctuate from period to period and can be
comprised of a small number of customers that account for a
significant portion of the Company’s revenue; the Company’s level
of success in obtaining coverage and adequate reimbursement and
collectability levels from third-party payors for its tests and
testing services; the Company’s level of success in establishing
and obtaining the intended benefits from partnerships, strategic
investments, joint ventures, acquisitions, or other relationships;
the success of the Company’s development efforts, including the
Company’s ability to progress its candidates through clinical
trials on the timelines expected; the Company’s compliance with the
various evolving and complex laws and regulations applicable to its
business and its industry; and the Company’s ability to protect its
proprietary technology and intellectual property. As a result of
these risks and uncertainties, forward-looking statements should
not be relied on or viewed as predictions of future events.
The forward-looking statements made in this press release speak
only as of the date of this press release, and the Company assumes
no obligation to update publicly any such forward-looking
statements to reflect actual results or to changes in expectations,
except as otherwise required by law.
The Company’s reports filed with the U.S. Securities and
Exchange Commission, or the SEC, including its annual report on
Form 10-K for the year ended December 31, 2021 filed with the SEC
on February 28, 2022 and the other reports it files from time to
time, including subsequently filed annual, quarterly and current
reports, are made available on the Company’s website upon their
filing with the SEC. These reports contain more information about
the Company, its business and the risks affecting its business, as
well as its results of operations for the periods covered by the
financial results included in this press release.
FULGENT GENETICS, INC.
Condensed Consolidated Balance Sheet
Data
December 31, 2022 and 2021
(in thousands)
December 31,
2022
2021
ASSETS:
Cash and cash equivalents
$
79,506
$
164,894
Investments in marketable securities
773,377
770,652
Accounts receivable, net
52,749
138,912
Property, plant, and equipment, net
81,353
62,287
Other assets
399,068
141,975
Total assets
$
1,386,053
$
1,278,720
LIABILITIES & EQUITY:
Accounts payable, accrued liabilities and
other liabilities
$
116,178
$
112,840
Total stockholders' equity
1,269,875
1,165,880
Total liabilities & equity
$
1,386,053
$
1,278,720
FULGENT GENETICS, INC.
Condensed Consolidated Statement of
Operations Data
Three and Twelve Months Ended December
31, 2022 and 2021
(in thousands, except per share
data)
(unaudited)
Three Months Ended December
31,
Twelve Months Ended December
31,
2022
2021
2022
2021
Revenue
$
67,704
$
251,671
$
618,968
$
992,584
Cost of revenue (1)
54,717
62,134
252,067
215,533
Gross profit
12,987
189,537
366,901
777,051
Operating expenses:
Research and development (1)
8,509
7,464
28,910
24,219
Selling and marketing (1)
10,253
8,200
38,918
24,439
General and administrative (1)
28,793
22,102
111,074
50,732
Amortization of intangible assets
2,010
911
6,497
1,708
Restructuring costs
(26
)
—
2,975
—
Total operating expenses
49,539
38,677
188,374
101,098
Operating (loss) income
(36,552
)
150,860
178,527
675,953
Interest and other income (expense),
net
3,090
(35
)
5,498
1,347
(Loss) income before income taxes and gain
on equity method investment
(33,462
)
150,825
184,025
677,300
(Benefit from) provision for income
taxes
(9,386
)
47,148
42,102
174,795
(Loss) income before gain on equity method
investment
(24,076
)
103,677
141,923
502,505
Gain on equity method investment
—
—
—
3,734
Net (loss) income from consolidated
operations
(24,076
)
103,677
141,923
506,239
Net loss attributable to noncontrolling
interests
244
662
1,480
1,125
Net (loss) income attributable to
Fulgent
$
(23,832
)
$
104,339
$
143,403
$
507,364
Net (loss) income per common share
attributable to Fulgent:
Basic
$
(0.80
)
$
3.48
$
4.76
$
17.25
Diluted
$
(0.80
)
$
3.34
$
4.63
$
16.38
Weighted average common shares:
Basic
29,625
29,964
30,097
29,408
Diluted
29,625
31,202
30,964
30,976
(1) Equity-based compensation expense was
allocated as follows:
Cost of revenue
$
2,521
$
1,235
$
8,704
$
3,563
Research and development
3,339
1,865
10,449
6,326
Selling and marketing
1,225
774
4,373
2,513
General and administrative
2,937
1,146
9,114
3,480
Total equity-based compensation
expense
$
10,022
$
5,020
$
32,640
$
15,882
FULGENT GENETICS, INC.
Non-GAAP Income (Loss)
Reconciliation
Three and Twelve Months Ended December
31, 2022 and 2021
(in thousands, except per share
data)
Three Months Ended December
31,
Twelve Months Ended December
31,
2022
2021
2022
2021
Net (loss) income attributable to
Fulgent
$
(23,832
)
$
104,339
$
143,403
$
507,364
Amortization of intangible assets
2,010
911
6,497
1,708
Restructuring costs
(26
)
—
2,975
—
Acquisition-related costs
1,359
—
7,934
—
Equity-based compensation expense
10,022
5,020
32,640
15,882
Non-GAAP tax effect (1)
(3,742
)
(1,601
)
(14,013
)
(4,749
)
Gain on equity method investment
—
—
—
(3,734
)
Non-GAAP (loss) income attributable to
Fulgent
$
(14,209
)
$
108,669
$
179,436
$
516,471
Net (loss) income per common share
attributable to Fulgent:
Basic
$
(0.80
)
$
3.48
$
4.76
$
17.25
Diluted
$
(0.80
)
$
3.34
$
4.63
$
16.38
Non-GAAP (loss) income per common share
attributable to Fulgent:
Basic
$
(0.48
)
$
3.63
$
5.96
$
17.56
Diluted
$
(0.48
)
$
3.48
$
5.79
$
16.67
Weighted average common shares:
Basic
29,625
29,964
30,097
29,408
Diluted
29,625
31,202
30,964
30,976
(1) Tax rates as follows:
Corporate tax rate of 28% for the three
and twelve months ended December 31, 2022.
Corporate tax rate of 27% for the three
and twelve months ended December 31, 2021.
FULGENT GENETICS, INC.
Non-GAAP Adjusted EBITDA
Reconciliation
Three and Twelve Months Ended December
31, 2022 and 2021
(in thousands)
Three Months Ended December
31,
Twelve Months Ended December
31,
2022
2021
2022
2021
Net (loss) income attributable to
Fulgent
$
(23,832
)
$
104,339
$
143,403
$
507,364
Interest income, net
(3,023
)
(224
)
(4,610
)
(1,737
)
(Benefit from) provision for income
taxes
(9,386
)
47,148
42,102
174,795
Restructuring costs
(26
)
—
2,975
—
Acquisition-related costs
1,359
—
7,934
—
Equity-based compensation expense
10,022
5,020
32,640
15,882
Depreciation and amortization
9,802
3,491
32,662
11,004
Gain on equity method investment
—
—
—
(3,734
)
Adjusted EBITDA
$
(15,084
)
$
159,774
$
257,106
$
703,574
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230228006214/en/
Investor Relations Contact: The Blueshirt Group Melanie
Solomon, melanie@blueshirtgroup.com
Fulgent Genetics (NASDAQ:FLGT)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Fulgent Genetics (NASDAQ:FLGT)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024